Literature DB >> 21761255

An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Heather Keen1, Bernd Pichler, Damaris Kukuk, Olivier Duchamp, Olivier Raguin, Aoife Shannon, Nichola Whalley, Vivien Jacobs, Juliana Bales, Neill Gingles, Sally-Ann Ricketts, Stephen R Wedge.   

Abstract

PURPOSE: The aim of this study is to assess the variability of 2-deoxy-2-[(18)F]fluoro-D: -glucose ([(18)F]-FDG) and 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake in pre-clinical tumor models and examine the relationship between imaging data and related histological biomarkers. PROCEDURES: [(18)F]-FDG and [(18)F]-FLT studies were carried out in nine human tumor xenograft models in mice. A selection of the models underwent histological analysis for endpoints relevant to radiotracer uptake. Comparisons were made between in vitro uptake, in vivo imaging, and ex vivo histopathology data using quantitative and semi-quantitative analysis.
RESULTS: In vitro data revealed that [1-(14)C]-2-deoxy-D: -glucose ([(14)C]-2DG) uptake in the tumor cell lines was variable. In vivo, [(18)F]-FDG and [(18)F]-FLT uptake was highly variable across tumor types and uptake of one tracer was not predictive for the other. [(14)C]-2DG uptake in vitro did not predict for [(18)F]-FDG uptake in vivo. [(18)F]-FDG SUV was inversely proportional to Ki67 and necrosis levels and positively correlated with HKI. [(18)F]-FLT uptake positively correlated with Ki67 and TK1.
CONCLUSION: When evaluating imaging biomarkers in response to therapy, the choice of tumor model should take into account in vivo baseline radiotracer uptake, which can vary significantly between models.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21761255     DOI: 10.1007/s11307-011-0504-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  49 in total

1.  Monitoring tumor response to therapy with 18F-FLT PET.

Authors:  Wolfgang A Weber
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

2.  Quantitating tumor glucose metabolism with FDG and PET.

Authors:  R A Hawkins; Y Choi; S C Huang; C Messa; C K Hoh; M E Phelps
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

3.  Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts.

Authors:  F Kallinowski; K H Schlenger; S Runkel; M Kloes; M Stohrer; P Okunieff; P Vaupel
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

4.  FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models.

Authors:  U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick
Journal:  Nucl Med Biol       Date:  1994-08       Impact factor: 2.408

5.  Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells.

Authors:  Aren van Waarde; Lukas B Been; Kiichi Ishiwata; Rudi A Dierckx; Philip H Elsinga
Journal:  J Nucl Med       Date:  2006-09       Impact factor: 10.057

6.  Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.

Authors:  Jinyu Gu; Hirofumi Yamamoto; Hiroki Fukunaga; Katsuki Danno; Ichiro Takemasa; Masataka Ikeda; Mitsuaki Tatsumi; Mitsugu Sekimoto; Jun Hatazawa; Tsunehiko Nishimura; Morito Monden
Journal:  Dig Dis Sci       Date:  2006-11-02       Impact factor: 3.199

7.  Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.

Authors:  Hui Wang; Jinming Zhang; Jiahe Tian; Baolin Qu; Tianran Li; Yingmao Chen; Jian Liu; Shan Wang
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

8.  P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.

Authors:  Satoru Seo; Etsuro Hatano; Tatsuya Higashi; Akio Nakajima; Yuji Nakamoto; Masaharu Tada; Nobuyuki Tamaki; Keiko Iwaisako; Koji Kitamura; Iwao Ikai; Shinji Uemoto
Journal:  Int J Oncol       Date:  2009-05       Impact factor: 5.650

9.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.

Authors:  K Hamacher; H H Coenen; G Stöcklin
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

10.  Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.

Authors:  Andreas K Buck; Clemens Kratochwil; Gerhard Glatting; Malik Juweid; Martin Bommer; Djurdja Tepsic; Andreas T J Vogg; Torsten Mattfeldt; Bernd Neumaier; Peter Möller; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-31       Impact factor: 9.236

View more
  7 in total

1.  The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.

Authors:  Valerie S Honndorf; Holger Schmidt; Stefan Wiehr; Hans F Wehrl; Leticia Quintanilla-Martinez; Anke Stahlschmidt; Hervé Barjat; Sally-Ann Emmas; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

2.  Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.

Authors:  Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; David Thomae; Patrick Pauwels; Tim Van den Wyngaert; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

3.  Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.

Authors:  Sven De Bruycker; Christel Vangestel; Tim Van den Wyngaert; Leonie Wyffels; An Wouters; Patrick Pauwels; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

4.  Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.

Authors:  Alan Desilva; Melinda Wuest; Monica Wang; Jeff Hummel; Karen Mossman; Frank Wuest; Mary M Hitt
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

5.  Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.

Authors:  Heather G Keen; Sally-Ann Ricketts; Juliana Maynard; Armelle Logie; Rajesh Odedra; Aoife M Shannon; Stephen R Wedge; Sylvie M Guichard
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

6.  Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV.

Authors:  Arthur Varoquaux; Olivier Rager; Karl-Olof Lovblad; Karen Masterson; Pavel Dulguerov; Osman Ratib; Christoph D Becker; Minerva Becker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

7.  The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.

Authors:  Kathrin Heinzmann; Davina Jean Honess; David Yestin Lewis; Donna-Michelle Smith; Christopher Cawthorne; Heather Keen; Sandra Heskamp; Sonja Schelhaas; Timothy Howard Witney; Dmitry Soloviev; Kaye Janine Williams; Andreas Hans Jacobs; Eric Ofori Aboagye; John Richard Griffiths; Kevin Michael Brindle
Journal:  EJNMMI Res       Date:  2016-08-11       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.